Literature DB >> 34234494

The Incidence of Metabolic Syndrome and the Valid Blood Pressure Cutoff Value for Predicting Metabolic Syndrome Within the Normal Blood Pressure Range in the Population Over 40 Years Old in Guiyang, China.

Li Ma1, Hong Li1,2, Huijun Zhuang1, Qiao Zhang1, Nianchun Peng1, Ying Hu1, Na Han1, Yuxing Yang1, Lixin Shi1.   

Abstract

PURPOSE: The study was conducted to investigate metabolic syndrome (MS) incidence within the normal blood pressure (BP) range in a population over 40 years old in an urban area of Guiyang, Guizhou Province, China, and to identify a valid BP cutoff value for predicting MS.
MATERIALS AND METHODS: Data from this study are based on the Risk Evaluation of cAncers in Chinese diabeTic Individuals: a lONgitudinal (REACTION) study. In total, 2935 subjects in the normal BP range and without MS (795 males, 2140 females) aged 40-80 years were included in this study. Follow-up subjects were classified by baseline BP and grouped by age. After the 3-year follow-up, the MS incidence and valid BP cutoff value for predicting MS were calculated for subjects within the normal BP range.
RESULTS: After the 3-year follow-up study, the crude and standardized MS incidences in the cohort were 19.83% and 16.89% for follow-up subjects, respectively, with incidences of 10.94% and 10.50% for males and 23.13% and 20.66% for females. The incidence of MS in normotensive subjects (15.53%) was lower than that in subjects with high-normal BP (29.08%). After adjusting for age, sex, BMI, smoking, and drinking, the risk of having MS in the high-normal BP group was 1.823-fold [HR 1.823 95% CI (1.538-2.162)] higher than that in the normotensive group. The ROC curve showed that the BP cutoff values were more than 117/74 mmHg in males and 112/74 mmHg in females.
CONCLUSION: When BP was within the normal range, the incidence of MS in participants was very high. The MS incidence was higher among high-normal BP subjects than among normotensive subjects, as was the risk of having MS. The valid BP cutoff value for predicting MS in the population was 117/74 mmHg in males and 112/74 mmHg in females. Currently, epidemiological investigations are needed to determine whether a lower BP cutoff value is needed in diagnosing MS.
© 2021 Ma et al.

Entities:  

Keywords:  cutoff value; high-normal blood pressure; incidence; metabolic syndrome; normotensive

Year:  2021        PMID: 34234494      PMCID: PMC8255645          DOI: 10.2147/DMSO.S308923

Source DB:  PubMed          Journal:  Diabetes Metab Syndr Obes        ISSN: 1178-7007            Impact factor:   3.168


  32 in total

1.  Diabetes and cancer: findings from the REACTION study:REACTION.

Authors:  Guang Ning; Zachary Bloomgarden
Journal:  J Diabetes       Date:  2015-01-13       Impact factor: 4.006

2.  The relationship between insulin-sensitive obesity and cardiovascular diseases in a Chinese population: results of the REACTION study.

Authors:  Jieli Lu; Yufang Bi; Tiange Wang; Weiqing Wang; Yiming Mu; Jiajun Zhao; Chao Liu; Lulu Chen; Lixin Shi; Qiang Li; Qin Wan; Shengli Wu; Guijun Qin; Tao Yang; Li Yan; Yan Liu; Guixia Wang; Zuojie Luo; Xulei Tang; Gang Chen; Yanan Huo; Zhengnan Gao; Qing Su; Zhen Ye; Youming Wang; Huacong Deng; Xuefeng Yu; Feixia Shen; Li Chen; Liebing Zhao; Meng Dai; Min Xu; Yu Xu; Yuhong Chen; Shenghan Lai; Guang Ning
Journal:  Int J Cardiol       Date:  2014-01-25       Impact factor: 4.164

3.  Levels of Systolic and Diastolic Blood Pressure and Their Relation to Incident Metabolic Syndrome.

Authors:  Ju Young Jung; Chang-Mo Oh; Joong-Myung Choi; Jae-Hong Ryoo; Pil-Wook Chung; Hyun Pyo Hong; Sung Keun Park
Journal:  Cardiology       Date:  2019-07-12       Impact factor: 1.869

4.  Increased incidence of metabolic syndrome in older men with high normotension.

Authors:  Leay-Kiaw Er; Yen-Lin Chen; Dee Pei; Shu Chuen Lau; Shi-Wen Kuo; Chun-Hsien Hsu
Journal:  Aging Male       Date:  2012-10-05       Impact factor: 5.892

5.  Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies.

Authors:  Sarah Lewington; Robert Clarke; Nawab Qizilbash; Richard Peto; Rory Collins
Journal:  Lancet       Date:  2002-12-14       Impact factor: 79.321

6.  Predictive value of prehypertension for metabolic syndrome, diabetes, and coronary heart disease among Turks.

Authors:  Altan Onat; Mehmet Yazici; Günay Can; Zekeriya Kaya; Serkan Bulur; Gülay Hergenç
Journal:  Am J Hypertens       Date:  2008-06-12       Impact factor: 2.689

7.  Body mass index and age at natural menopause: an international pooled analysis of 11 prospective studies.

Authors:  Dongshan Zhu; Hsin-Fang Chung; Nirmala Pandeya; Annette J Dobson; Diana Kuh; Sybil L Crawford; Ellen B Gold; Nancy E Avis; Graham G Giles; Fiona Bruinsma; Hans-Olov Adami; Elisabete Weiderpass; Darren C Greenwood; Janet E Cade; Ellen S Mitchell; Nancy F Woods; Eric J Brunner; Mette Kildevæld Simonsen; Gita D Mishra
Journal:  Eur J Epidemiol       Date:  2018-02-19       Impact factor: 8.082

8.  New non-invasive method for early detection of metabolic syndrome in the working population.

Authors:  Manuel Romero-Saldaña; Francisco J Fuentes-Jiménez; Manuel Vaquero-Abellán; Carlos Álvarez-Fernández; Guillermo Molina-Recio; José López-Miranda
Journal:  Eur J Cardiovasc Nurs       Date:  2016-01-07       Impact factor: 3.908

9.  Incidence of metabolic syndrome and relative importance of five components as a predictor of metabolic syndrome: 5-year follow-up study in Korea.

Authors:  Jun Hyun Hwang; Sin Kam; Ji-yeon Shin; Jong-Yeon Kim; Kyung-Eun Lee; Gi-Hong Kwon; Byung-Yeol Chun; Shung Chull Chae; Dong Heon Yang; Hun Sik Park; Tae-Yoon Hwang
Journal:  J Korean Med Sci       Date:  2013-11-26       Impact factor: 2.153

10.  The clinical value of metabolic syndrome and risks of cardiometabolic events and mortality in the elderly: the Rotterdam study.

Authors:  Thijs T W van Herpt; Abbas Dehghan; Mandy van Hoek; M Arfan Ikram; Albert Hofman; Eric J G Sijbrands; Oscar H Franco
Journal:  Cardiovasc Diabetol       Date:  2016-04-27       Impact factor: 9.951

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.